Mostrar el registro sencillo del ítem

dc.rights.licenseLicencia de Creative Commons Reconocimiento-NoComercial-CompartirIgual 4.0 Internacionalspa
dc.contributor.authorBermúdez, Valmore
dc.contributor.authorTorres, Wheeler
dc.contributor.authorSalazar, Juan
dc.contributor.authorMartínez, María Sofía
dc.contributor.authorRojas, Edward
dc.contributor.authorOlivar, Luis Carlos
dc.contributor.authorLameda, Victor
dc.contributor.authorOrtega, Ángel
dc.contributor.authorRamírez, Paola
dc.contributor.authorRojas, Milagros
dc.contributor.authorRastogi, Sheena
dc.contributor.authorD’Addosio, Rosanna
dc.contributor.authorHoedebecke, Kyle
dc.contributor.authorGraterol, Modesto
dc.contributor.authorGraterol, Resemily
dc.contributor.authorWilches, Sandra
dc.contributor.authorCabrera de Bravo, Mayela
dc.contributor.authorRojas-Quintero, Joselyn
dc.date.accessioned2019-01-21T16:06:44Z
dc.date.available2019-01-21T16:06:44Z
dc.date.issued2018-09-20
dc.identifier.issn20461402
dc.identifier.urihttp://hdl.handle.net/20.500.12442/2459
dc.description.abstractBackground: Non-high density lipoprotein cholesterol (non-HDL-c) has emerged as an important tool in primary prevention of atherosclerotic cardiovascular disease (ASCVD), especially among those at high risk. The main objective of this study was to evaluate the predictive value of non-HDL-c for the coexistence aggregation of multiple ASCVD risk factors and compare this with LDL-c in general subjects with normal or near normal triglycerides from Maracaibo city in Venezuela. Methods: This is a descriptive, cross-sectional study with a randomized multistage sampling. 2026 subjects were selected for this study, all were adults ≥18 years old of both genders and inhabitants of Maracaibo city, Venezuela. A complete history and physical medical assessment was performed. A multivariate logistic regression model was used to determine the odds ratio (CI95%) for the coexistence of multiple risk factors for ASCVD. Results: The median (p25-p75) of non-HDL-c was 143 mg/dL (114-174 mg/dL). 52.1% (n=1056) of the sample were women, with a median of 144 mg/dL (115-174 mg/dL) among women and 143 mg/dL (114-17 4mg/dL) among men; p=0.740. Individuals ≥50 years old, smokers, those with hypertension, obesity, diabetes, high waist circumference and elevated hs-C Reactive Protein, all had higher levels of non-HDL-c. A lower median was observed among those <30 years of age with elevated physical activity levels in their leisure time. Non-HDL-c between 130-159 mg/dL (OR=2.44; CI 95%=1.48-4.02; p<0.001) and ≥160 mg/dL (OR=3.28; CI 95%=1.72-6.23; p<0.001) was associated with greater risk of coexistent multiple risk factors for ASCVD, albeit LDL-c was not significant in the multivariate model. Conclusions: Elevated non-HDL-c was associated with conglomeration of multiple risk factors for ASCVD. This suggests evaluation of non-HDL-c may be of better utility in primary care for early identification of subjects for high risk of ASCVD. Future research might focus on the influence of non-HDL-c in cardiovascular mortality.eng
dc.language.isoengeng
dc.publisherF1000 Research Ltd.eng
dc.sourceF1000Researcheng
dc.sourceVol. 7, No. 504 (2018)eng
dc.source.urihttps://f1000research.com/articles/7-504/v1eng
dc.subjectnon-HDL-ceng
dc.subjectLDL-ceng
dc.subjectCholesteroleng
dc.subjectASCVDeng
dc.subjectRisk factorseng
dc.subjectCoronary Artery Diseaseeng
dc.titleNon-HDL cholesterol is better than LDL-c at predicting atherosclerotic cardiovascular disease risk factors clustering, even in subjects with near-to-normal triglycerides: A report from a Venezuelan populationspa
dc.typearticleeng
dcterms.referencesRoth GA, Huffman MD, Moran AE, et al.: Global and Regional Patterns in Cardiovascular Mortality From 1990 to 2013. Circulation. 2015; 132(17): 1667–1678.eng
dcterms.referencesPasterkamp C, Falk E: Atherosclerotic plaque rupture: an overview. Journal of Clinical and Basic Cardiology. 2000; 3(2): 81–6.eng
dcterms.referencesBoyle JJ: Macrophage activation in atherosclerosis: pathogenesis and pharmacology of plaque rupture. Curr Vasc Pharmacol. 2005; 3(1): 63–8.eng
dcterms.referencesKannel WB, Dawber TR, Thomas HE Jr, et al.: Comparison Of Serum Lipids In The Prediction Of Coronary Heart Disease. Framingham Study Indicates That Cholesterol Level And Blood Pressure Are Major Factors In Coronary Heart Disease; Effect Of Obesity And Cigarette Smoking Also Noted. R I Med J. 1965; 48: 243–50.eng
dcterms.referencesScandinavian Simvastatin Survival Study Group: Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994; 344(8934): 1383–9.eng
dcterms.referencesLong-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group: Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med. 1998; 339(19): 1349–57.eng
dcterms.referencesThe Heart Protection Study Collaborative Group: MRC/BHF heart protection study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomized placebo-controlled trial. ACC Curr J Rev. 2002; 11(6): 34–5.eng
dcterms.referencesWillerson JT: Effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Circulation. 1996; 94(12): 3054.eng
dcterms.referencesJepsen AM, Langsted A, Varbo A, et al.: Increased Remnant Cholesterol Explains Part of Residual Risk of All-Cause Mortality in 5414 Patients with Ischemic Heart Disease. Clin Chem. 2016; 62(4): 593–604.eng
dcterms.referencesSampson UK, Fazio S, Linton MF: Residual cardiovascular risk despite optimal LDL cholesterol reduction with statins: the evidence, etiology, and therapeutic challenges. Curr Atheroscler Rep. 2012; 14(1): 1–10.eng
dcterms.referencesFruchart JC, Davignon J, Hermans MP, et al.: Residual macrovascular risk in 2013: what have we learned? Cardiovasc Diabetol. 2014; 13(1): 26.eng
dcterms.referencesFukuyama N, Homma K, Wakana N, et al.: Validation of the Friedewald Equation for Evaluation of Plasma LDL-Cholesterol. J Clin Biochem Nutr. 2008; 43(1): 1–5.eng
dcterms.referencesBermúdez V, Salazar J, Calvo M, et al.: Importance of high triglycerides levels between novel coronary risk factors. Revista Colombiana de Cardiología. 2017; 24(6): 583–591.eng
dcterms.referencesThe Emerging Risk Factors Collaboration, Di Angelantonio E, Sarwar N, et al.: Major lipids, apolipoproteins, and risk of vascular disease. JAMA. 2009; 302(18): 1993–2000.eng
dcterms.referencesGhodsi S, Meysamie A, Abbasi M, et al.: Non-high-density lipoprotein fractions are strongly associated with the presence of metabolic syndrome independent of obesity and diabetes: a population-based study among Iranian adults. J Diabetes Metab Disord. 2017; 16: 25.eng
dcterms.referencesMoriyama K, Takahashi E: Non-HDL Cholesterol is a More Superior Predictor of Small-Dense LDL Cholesterol than LDL Cholesterol in Japanese Subjects with TG Levels <400 mg/dL. J Atheroscler Thromb. 2016; 23(9): 1126–37.eng
dcterms.referencesBermúdez V, Marcano RP, Cano C, et al.: The Maracaibo city metabolic syndrome prevalence study: design and scope. Am J Ther. 2010; 17(3): 288–94.eng
dcterms.referencesMéndez-Castellano H, De Méndez M: Estratificación social y biología humana: método de Graffar modificado. Arch Venez Pueric Pediatr. 1986; 49: 93–104.spa
dcterms.referencesBermúdez V, Miquilena E, Salazar J, et al.: Smoking Habit in Adult Population from Maracaibo City, Venezuela. Int J Respir Pulm Med. 2016; 3(6): 61.eng
dcterms.referencesBermúdez V, Torres Y, Apruzzese V, et al.: Alcohol drinking patterns in the adult population from the Maracaibo municipality, Zulia – Venezuela. Revista Latinoamericana de Hipertensión. 2014; 9(3): 21–8.eng
dcterms.referencesInternational Physical Activity Questionnaire (IPAQ) and New Zealand Physical Activity Questionnaire (NZPAQ): A doubly labelled water validation. J Sci Med Sport. 2007; 10(1): 52.eng
dcterms.referencesChobanian AV, Bakris GL, Black HR, et al.: The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA. 2003; 289(19): 2560–71.eng
dcterms.referencesWHO: Obesity: preventing and managing the global epidemic. Report of a WHO Consultation. World Health Organ Tech Rep Ser. 2000; 894: i–xii, 1–253.eng
dcterms.referencesHealth Statistics: NHANES III reference manuals and reports (CDROM).Hyattsvillem, MD: Centers for Disease Control and Prevention. 1996.eng
dcterms.referencesBermúdez V, Rojas J, Salazar J, et al.: Sensitivity and Specificity Improvement in Abdominal Obesity Diagnosis Using Cluster Analysis during Waist Circumference Cut-Off Point Selection. J Diabetes Res. 2015; 2015: 1–14, 750265eng
dcterms.referencesAmerican Diabetes Association: 2. Classification and Diagnosis of Diabetes. Diabetes Care. 2017; 40(Suppl 1): S11–S24.eng
dcterms.referencesBermúdez V, Cabrera M, Mendoza L, et al.: High-sensitivity c-Reactive protein epidemiological behavior in adult individuals from Maracaibo, Venezuela. Revista Latinoamericana de Hipertensión. 2013; 8(1): 22–29.eng
dcterms.referencesBermúdez V, Rojas J, Martínez MS, et al.: Epidemiologic Behavior and Estimation of an Optimal Cut-Off Point for Homeostasis Model Assessment- 2 Insulin Resistance: A Report from a Venezuelan Population. Int Sch Res Notices. 2014; 2014: 1–10, 616271.eng
dcterms.referencesFriedewald WT, Levy RI, Fredrickson DS: Estimation of the Concentration of Low-Density Lipoprotein Cholesterol in Plasma, Without Use of the Preparative Ultracentrifuge. Clin Chem. 1972; 18(6): 499–502.eng
dcterms.referencesJellinger PS, Handelsman Y, Rosenblit PD, et al.: AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY GUIDELINES FOR MANAGEMENT OF DYSLIPIDEMIA AND PREVENTION OF CARDIOVASCULAR DISEASE - EXECUTIVE SUMMARYComplete Appendix to Guidelines available at http://journals.aace. com. Endocr Pract. 2017; 23(4): 479–497.eng
dcterms.referencesGrundy SM, Cleeman JI, Merz CN, et al.: Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation. 2004; 110(2): 227–39.eng
dcterms.referencesStone NJ, Robinson JG, Lichtenstein AH, et al.: 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2014; 63: 2889–934.eng
dcterms.referencesHarper CR, Jacobson TA: Using apolipoprotein B to manage dyslipidemic patients: time for a change? Mayo Clin Proc. 2010; 85(5): 440–5.eng
dcterms.referencesRobinson JG, Wang S, Smith BJ, et al.: Meta-analysis of the relationship between non-high-density lipoprotein cholesterol reduction and coronary heart disease risk. J Am Coll Cardiol. 2009; 53(4): 316–22.eng
dcterms.referencesHelgadottir A, Gretarsdottir S, Thorleifsson G, et al.: Variants with large effects on blood lipids and the role of cholesterol and triglycerides in coronary disease. Nat Genet. 2016; 48(6): 634–9.eng
dcterms.referencesBittner V: Non-HDL Cholesterol: Measurement, Interpretation and Significance. John Hopkins Advanced Studies in Medicine. 2007; 7(1): 8–11.eng
dcterms.referencesKumar BV, Guntakalla YR, Thomas Z, et al.: Role of Non High Density Lipoprotein Cholesterol (Non HDL-C) in Predicting Coronary Artery Disease. Indian Journal of Pharmacy Practice. 2015; 8(4): 166–170.eng
dcterms.referencesArsenault BJ, Rana JS, Stroes ES, et al.: Beyond low-density lipoprotein cholesterol: respective contributions of non-high-density lipoprotein cholesterol levels, triglycerides, and the total cholesterol/high-density lipoprotein cholesterol ratio to coronary heart disease risk in apparently healthy men and women. J Am Coll Cardiol. 2009; 55(1): 35–41.eng
dcterms.referencesLu W, Resnick HE, Jablonski KA, et al.: Non-HDL cholesterol as a predictor of cardiovascular disease in type 2 diabetes: the strong heart study. Diabetes Care. 2003; 26(1): 16–23.eng
dcterms.referencesWriting Committee, Lloyd-Jones DM, Morris PB, et al.: 2016 ACC Expert Consensus Decision Pathway on the Role of Non-Statin Therapies for LDLCholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk: A Report of the American College of Cardiology Task Force on Clinical Expert Consensus Documents. J Am Coll Cardiol. 2016; 68(1): 92–125.eng
dcterms.referencesLin FJ, Tseng WK, Yin WH, et al.: Residual Risk Factors to Predict Major Adverse Cardiovascular Events in Atherosclerotic Cardiovascular Disease Patients with and without Diabetes Mellitus. Sci Rep. 2017; 7(1): 9179.eng
dcterms.referencesHwang YC, Ahn HY, Park SW, et al.: Apolipoprotein B and non-HDL cholesterol are more powerful predictors for incident type 2 diabetes than fasting glucose or glycated hemoglobin in subjects with normal glucose tolerance: a 3.3-year retrospective longitudinal study. Acta Diabetol. 2014; 51(6): 941–6.eng
dcterms.referencesBermúdez V, Pacheco M, Rojas J, et al.: Epidemiologic behavior of obesity in the Maracaibo City metabolic syndrome prevalence study. PLoS One. 2012; 7(4): e35392.eng
dcterms.referencesDegoma EM, Davis MD, Dunbar RL, et al.: Discordance between non-HDLcholesterol and LDL-particle measurements: results from the Multi-Ethnic Study of Atherosclerosis. Atherosclerosis. 2013; 229(2): 517–23.eng
dcterms.referencesKilgore M, Muntner P, Woolley JM, et al.: Discordance between high non-HDL cholesterol and high LDL-cholesterol among US adults. J Clin Lipidol. 2014; 8(1): 86–93.eng
dcterms.referencesRodriguez CJ, Daviglus ML, Swett K, et al.: Dyslipidemia patterns among Hispanics/Latinos of diverse background in the United States. Am J Med. 2014; 127(12): 1186–94.e1.eng
dcterms.referencesWang Z, Manichukal A, Goff DC Jr, et al.: Genetic associations with lipoprotein subfraction measures differ by ethnicity in the multi-ethnic study of atherosclerosis (MESA). Hum Genet. 2017; 136(6): 715–726.eng
dcterms.referencesBermúdez V, Torres W, Salazar J, et al.: Dataset 1 in: Non-HDL cholesterol is better than LDL-c at predicting atherosclerotic cardiovascular disease risk factors clustering, even in subjects with near-to-normal triglycerides: A report from a Venezuelan population. F1000Research. 2018.eng
dc.rights.accessrightsinfo:eu-repo/semantics/openAccess


Ficheros en el ítem

Thumbnail

Este ítem aparece en la(s) siguiente(s) colección(ones)

  • Artículos [1351]
    Artículos científicos evaluados por pares

Mostrar el registro sencillo del ítem